Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications association between tumor necrosis factor inhibitor tnfi therapy changes c reactive
… health-related quality of life (HRQOL) in 3 different tumor types using data collected across 4 clinical trials. … only patient-reported outcomes data found no difference between the client’s product and placebo groups. OUR APPROACH …
FDA Rare Disease Day 2024 Virtual Public Meeting Share on: Friday, March 1, 2024, 9am - 4:30pm Meeting Agenda & Links We are pleased that Carla (DeMuro) Romano, M.S., Vice President of Patient-Centered Outcomes Assessment at RTI Health Solutions, will be …
… like what’s it worth to a patient if: The dosing regimen changes from 3 times a day to 1? Length of treatment … decreases to 5 days instead of 10? The delivery mechanism changes from injection to pill? Efficacy increases or side …
… M Giner-Soriano, M Linder, O Scholle, A Arana Navarro, C Bui , C Laguna, A Prados-Torres, A Roso-Llorach, S … recommended risk-minimization measures, including labeling changes and communication to healthcare professionals. … Cilostazol's use was restricted to second-line therapy in case lifestyle modifications, including smoking …
… environment is constantly changing. Requirements vary between markets and need coordination across multiple areas …
… donations - but the number of donations is not the only factor that impacts the supply of these products. Loss can …
… possibly “designed” to allow excellent coordination between the heart and the PSC. Additional research …
… Alzheimer's Association International Conference (AAIC) Share on: … most quantitative research development. Romano (DeMuro) C, Bratlee-Whhitaker E , Hartry A, Mearns ES, Taylor J, … EL, Gnanasakthy K, Goss D, McLeod L, Edwards T, Poulos C, DiBenedetti D , Paulsen R. Poster Real-world effectiveness …
… Karanth S , Makari D, Stergiopoulos S, Goyal RK . Poster Association of health-related quality of life with efficacy … Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with …
… For individual drugs in development , we will see changes in strategy, particularly for phase 2b or 3, where … markets globally will face complex and wide-ranging changes. We help clients navigate these challenges throughout …